TOPページ
|
英語
日本語
|
CONNECT WITH US:
ホーム
JCNについて
サービス
お問い合わせ
会員企業ログイン
ホーム
プレスリリース一覧
China Medical System Holdings Ltd.
プレスリリース一覧
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 09, 2025 09:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type.
More info..
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 09, 2024 14:00 JST
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
More info..
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
Dec 02, 2024 22:30 JST
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
More info..
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Sep 24, 2024 22:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
Aug 16, 2024 14:00 JST
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023.
More info..
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
Aug 05, 2024 23:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00 JST
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development.
More info..
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Jun 25, 2024 21:46 JST
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China.
More info..
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
Jun 18, 2024 19:53 JST
More info..
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06 JST
More info..
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Apr 01, 2024 21:30 JST
More info..
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Mar 28, 2024 11:29 JST
More info..
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
Feb 04, 2024 10:00 JST
More info..
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
Jan 02, 2024 15:00 JST
More info..
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
Dec 13, 2023 18:36 JST
More info..
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Aug 24, 2023 21:00 JST
More info..
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Jun 12, 2023 21:00 JST
More info..
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..
CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Aug 26, 2022 19:00 JST
More info..
1
新着プレスリリース
Hola Prime Launches Transformative CSR Initiatives to Support Education, Health, and Sustainability
2025年02月08日 08時00分
TOYOTA、ハイエース(バン)に特別仕様車を設定
2025年02月07日 13時40分
トヨタ・モビリティ基金、交通事故死傷者ゼロを目指す「タテシナ会議」の分科会活動、取り組みの進展と今後の方向性を確認
2025年02月07日 13時40分
Winvest Group Powers Web3.0 Expansion with Multi-Channel Financing
2025年02月06日 23時30分
RentFi Launching, Making Real Estate Investment Available to Everyone
2025年02月06日 17時00分
マツダ、2025年度の参加型ブランド体験イベント「MAZDA FAN FESTA」の計画を発表
2025年02月06日 11時40分
富士通、世界最大のコネクティビティ関連展示会「MWC Barcelona 2025」に出展
2025年02月05日 14時30分
三菱造船、低圧液化CO₂内航輸送船の基本設計承認(AiP)を船級協会から取得
2025年02月05日 14時30分
トヨタ、米国ノースカロライナ州での車載用電池工場稼働開始
2025年02月05日 13時30分
トヨタ、上海市とカーボンニュートラルに関する包括的提携契約を締結
2025年02月05日 13時30分
トヨタ、2025年3月期 第3四半期決算を発表
2025年02月05日 13時30分
KKR、富士ソフトに対する第2回公開買付価格を1株9,850円に引き上げ
2025年02月04日 23時00分
QSEC-CEE 2025 Concludes with Breakthroughs in Quantum Cybersecurity
2025年02月04日 21時00分
富士通、最適なモダナイゼーションの計画策定を生成AIで支援する「Fujitsu 資産分析・可視化サービス」を提供開始
2025年02月04日 10時40分
国立長寿医療研究センターとエーザイ、認知機能低下リスクの低減と栄養に関するガイダンス、および 宅配食/ミールキット開発の手引きを作成し、食品関連企業へ提供開始
2025年02月03日 10時40分
富士通と東海国立大学機構、宇宙天気予測技術開発の月探査への適用に向けて、JAXAと共同研究を開始
2025年02月03日 10時40分
Honda、2024年12月度 四輪車 生産・販売・輸出実績を発表
2025年01月30日 15時00分
トヨタ、2024年 年間(1月-12月)販売・生産・輸出実績を発表
2025年01月30日 15時00分
三菱重工サーマルシステムズ、2024年度省エネ大賞で「資源エネルギー庁長官賞」を受賞
2025年01月30日 14時00分
三菱造船、インドネシア海上保安機構向けの巡視船を受注
2025年01月30日 12時00分
もっと見る >>